stockrowANI Pharmaceuticals, Inc.
ANIP Healthcare Drug Manufacturers Specialty & Generic
ANI Pharmaceuticals, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $883.4 million, up 43.8% from fiscal 2024.
- Revenue
- +27.6%
- EPS
- +29.4%
- Free cash flow
- +85.5%
- Total debt
- −96.2%
Quarter to September 2026, against a year earlier
Follow ANIP
Alert me
ANI Pharmaceuticals, Inc. (ANIP) P/E ratio
As of 5 November 2026, ANI Pharmaceuticals, Inc. (ANIP) trades at a P/E ratio of 13.3×. Over the past ten years it has ranged from 0.0× (September 2025) to 7,134× (July 2018); the current reading is higher than 42% of that period. That is below the Drug Manufacturers Specialty & Generic industry median of 20.5× and below the Healthcare sector median of 25.2×.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|---|---|
| FY2025 | 22.6× | — |
| FY2024 | 0.0× | — |
| FY2023 | 66.5× | — |
| FY2022 | 0.0× | — |
| FY2021 | 0.0× | — |
| FY2020 | 0.0× | — |
| FY2019 | 121× | 254.55% |
| FY2018 | 34.1× | — |
| FY2017 | 0.0× | — |
| FY2016 | 175× | 419.78% |
Quarterly newest first
| Period | P/E ratio | Change |
|---|---|---|
| Sep 2026 | 14.0× | (18.17%) |
| Jun 2026 | 17.1× | (8.40%) |
| Mar 2026 | 18.7× | (17.04%) |
| Dec 2025 | 22.6× | (57.90%) |
| 43 more quarters | Free account |
Against its own ten years
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| XERS Xeris Biopharma Holdings, Inc. compare | n/m |
| PRGO Perrigo Company plc compare | n/m |
| BCRX BioCryst Pharmaceuticals, Inc. compare | n/m |
| ALVO Alvotech compare | n/m |
| ANIP ANI Pharmaceuticals, Inc. | 13.3× |
| PAHC Phibro Animal Health Corporation compare | 14.0× |
| CRON Cronos Group Inc. compare | 21.9× |
| ETON Eton Pharmaceuticals, Inc. compare | 26.8× |
| PCRX Pacira BioSciences, Inc. compare | 38.4× |
| Drug Manufacturers Specialty & Generic industry median | 20.5× |
| Healthcare sector median | 25.2× |
| Market median | 17.9× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)